Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(1.94)
# 2,948
Out of 4,711 analysts
95
Total ratings
34.69%
Success rate
-5.45%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $36.82 | -2.23% | 4 | Nov 7, 2024 | |
| MCK McKesson | Maintains: Outperform | $560 → $680 | $579.74 | +17.29% | 4 | Nov 7, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $270 → $250 | $211.06 | +18.45% | 11 | Oct 24, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $7.5 → $10 | $9.55 | +4.71% | 12 | Oct 16, 2024 | |
| XRAY DENTSPLY SIRONA | Maintains: Outperform | $29 → $27 | $18.70 | +44.39% | 6 | Oct 8, 2024 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $9.44 | -4.66% | 2 | Oct 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Outperform | $270 → $265 | $197.27 | +34.33% | 5 | Oct 8, 2024 | |
| HCAT Health Catalyst | Maintains: Outperform | $8 → $10 | $7.09 | +41.04% | 5 | Oct 8, 2024 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $22 → $20 | $19.26 | +3.84% | 6 | Oct 8, 2024 | |
| DOCS Doximity | Maintains: In-Line | $34 → $45 | $57.83 | -22.19% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $75 | $44.36 | +69.07% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $1.97 | +103.05% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $250 → $240 | $228.61 | +4.98% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $18.70 | +22.99% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $153.10 | +7.77% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $105 → $115 | $118.28 | -2.77% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $20.07 | -0.35% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $12.78 | +105.40% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $8.32 | +80.29% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $3.03 | +263.04% | 2 | Jan 4, 2022 |
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $36.82
Upside: -2.23%
McKesson
Nov 7, 2024
Maintains: Outperform
Price Target: $560 → $680
Current: $579.74
Upside: +17.29%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $270 → $250
Current: $211.06
Upside: +18.45%
Walgreens Boots Alliance
Oct 16, 2024
Maintains: In-Line
Price Target: $7.5 → $10
Current: $9.55
Upside: +4.71%
DENTSPLY SIRONA
Oct 8, 2024
Maintains: Outperform
Price Target: $29 → $27
Current: $18.70
Upside: +44.39%
Teladoc Health
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $9.44
Upside: -4.66%
IQVIA Holdings
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $197.27
Upside: +34.33%
Health Catalyst
Oct 8, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $7.09
Upside: +41.04%
Fortrea Holdings
Oct 8, 2024
Maintains: In-Line
Price Target: $22 → $20
Current: $19.26
Upside: +3.84%
Doximity
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $57.83
Upside: -22.19%
Oct 8, 2024
Maintains: Outperform
Price Target: $62 → $75
Current: $44.36
Upside: +69.07%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $1.97
Upside: +103.05%
Sep 24, 2024
Maintains: In-Line
Price Target: $250 → $240
Current: $228.61
Upside: +4.98%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $18.70
Upside: +22.99%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $153.10
Upside: +7.77%
Aug 15, 2024
Maintains: In-Line
Price Target: $105 → $115
Current: $118.28
Upside: -2.77%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $20.07
Upside: -0.35%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $12.78
Upside: +105.40%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $8.32
Upside: +80.29%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $3.03
Upside: +263.04%